Article thumbnail

Risk factors for the development of depression in patients with hepatitis C taking interferon-α

By Kimberley J Smith, Suzanne Norris, Cliona O’Farrelly and Shane M O’Mara

Abstract

Interferon-α, currently used for the treatment of hepatitis C, is associated with a substantially elevated risk of depression. However, not everyone who takes this drug becomes depressed, so it is important to understand what particular factors may make some individuals more ‘at risk’ of developing depression than others. Currently there is no consensus as to why interferon-induced depression occurs and the range of putative risk factors is wide and diverse. The identification of risk factors prior to treatment may allow identification of patients who will become depressed on interferon, allowing the possibility of improved treatment support and rates of treatment adherence. Here, we consolidate and review the literature on risk factors, and we discuss the potential confounds within the research examined in order to better isolate the risk factors that may be important in the development of depression in these patients and which might help predict patients likely to become depressed on treatment. We suggest that interactions between psychobehavioral, genetic, and biological risk factors are of particular importance in the occurrence of depression in patients with hepatitis C taking interferon-α

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:3101888
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression.
  2. A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment.
  3. A link between stress and depression: shifts in the balance between the kynurenine and serotonin pathways of tryptophan metabolism and the etiology and pathophysiology of depression.
  4. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis
  5. (2002). A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry.
  6. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C.
  7. A review of sleep disturbance in hepatitis C.
  8. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression.
  9. (2001). Activation of vascular endothelial cell adhesion molecule expression by sickle blood cells. Pediatr Pathol Mol Med.
  10. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.
  11. Association between apolipoprotein E epsilon4 and neuropsychiatric symptoms during interferon alpha treatment for chronic hepatitis C.
  12. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy.
  13. (2006). Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. Biol Psychiatry.
  14. (2004). Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun.
  15. Biological basis of the behavior of sick animals.
  16. Burns in a suicide attempt related to psychiatric side effects of interferon.
  17. Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder.
  18. Central monoamines and their role in major depression.
  19. Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C.
  20. cognition and EEG changes during interferon alpha (alpha-IFN) treatment for chronic hepatitis C.
  21. Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis
  22. (2001). Compliance with therapy in patients with chronic hepatitis C: associations with psychiatric symptoms, interpersonal problems, and mode of acquisition. Dig Dis Sci.
  23. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression.
  24. (2009). Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality. Brain Behav Immun.
  25. (2002). Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci.
  26. Cytokines and major depression.
  27. (2004). Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry.
  28. (2005). Cytokines as a precipitant of depressive illness: animal and human studies. Curr Pharm Des.
  29. (2005). Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev.
  30. (1998). Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev.
  31. Cytokines sing the blues: inflammation and the pathogenesis of depression.
  32. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Aliment Pharmacol Ther.
  33. Depression and the serotonin transporter 5-HTTLPR polymorphism: a review and a hypothesis concerning gene-environment interaction.
  34. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction.
  35. Depression following pegylated interferon-alpha: characteristics and vulnerability.
  36. Depression from interferon therapy in patients with hepatitis C.
  37. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus.
  38. Depression, anemia and healthrelated quality of life in chronic hepatitis C.
  39. Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trial.
  40. (2010). Depressive symptoms following interferon-alpha therapy: mediated by immune-induced reductions in brain-derived neurotrophic factor?
  41. Diagnosis and treatment of chronic hepatitis C infection.
  42. Early prediction of major depression in chronic hepatitis C patients during peg-interferon alpha-2b treatment by assessment of vegetative-depressive symptoms after four weeks.
  43. (1997). Effect of interferon-alpha treatment of chronic hepatitis C on healthrelated quality of life. Dig Dis Sci.
  44. Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis
  45. (1992). Endotoxin-induced activation of cerebral catecholamine and serotonin metabolism: comparison with interleukin-1. J Pharmacol Exp Ther.
  46. Epidemiology of hepatitis C virus infection.
  47. (2008). From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci.
  48. (2009). Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry.
  49. (2005). Global epidemiology of hepatitis C virus infection. Lancet Infect Dis.
  50. Hematologic side effects of interferon and ribavirin therapy.
  51. (1998). Hepatitis C and depression. Depress Anxiety.
  52. Hepatitis C virus and depression in drug users.
  53. (2008). Hepatitis C virus therapy to date. Antivir Ther.
  54. Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients.
  55. (1993). High dose interferon treatment in chronic hepatitis
  56. (1998). How cells respond to interferons. Annu Rev Biochem.
  57. (2008). IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C. Brain Behav Immun.
  58. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res.
  59. (2006). Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C. Aliment Pharmacol Ther.
  60. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide.
  61. (2003). Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psychiatry.
  62. Incidence of interferon alfa-induced depression in patients with chronic hepatitis
  63. (2007). Incidence of psychiatric side effects during pegylated interferon- alpha retreatment in nonresponder hepatitis C virus-infected patients. Liver Int.
  64. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system.
  65. Increased risk for recurrent major depression in DYT1 dystonia mutation carriers.
  66. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene.
  67. Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population.
  68. (1998). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
  69. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
  70. (2002). Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry.
  71. Interferon alpha-induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha.
  72. Interferon and the central nervous system.
  73. Interferon treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C.
  74. (2010). Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol Psychiatry.
  75. Interferon-alpha influences tryptophan metabolism without inducing psychiatric side effects.
  76. (2003). Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry.
  77. Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol.
  78. Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches.
  79. (2004). Interleukin-1beta (IL-1beta) gene and increased risk for the depressive symptom-dimension in schizophrenia spectrum disorders.
  80. (2005). Irritability rather than depression during interferon treatment is linked to increased tryptophan catabolism. Psychosom Med.
  81. Labile anger during interferon alfa treatment is associated with a polymorphism in tumor necrosis factor alpha.
  82. Major depression during interferon-alpha treatment: vulnerability and prevention.
  83. Managing hepatitis C.
  84. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia.
  85. Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C – a critical review.
  86. (1998). Molecular basis of sickness behavior.
  87. Murine tumor necrosis factor alpha is transported from blood to brain in the mouse.
  88. (2005). Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma. Minerva Gastroenterol Dietol.
  89. (1994). Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem.
  90. Neuro-immune interactions in psychopathology with the example of interferon-alpha-induced depression.
  91. Neurobiology of depression: an integrated view of key findings.
  92. (2010). Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies. Neurobiol Dis.
  93. Neuropsychiatric adverse effects of interferon-alpha: recognition and management.
  94. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review.
  95. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther.
  96. (2002). Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther.
  97. Peginterferon alfa-2a in patients with chronic hepatitis C.
  98. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
  99. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
  100. Pegylated interferon and ribavirin-induced depression in chronic hepatitis C: role of personality.
  101. (1993). Peptides and blood-brain barrier transport. Physiol Rev.
  102. Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels.
  103. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment.
  104. Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatment. Psychiatry Res.
  105. Prediction of the depressive effects of interferon alfa therapy by the patient’s initial affective state.
  106. (2000). Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C. J Viral Hepat.
  107. (2007). Preventing relapse of major depression during interferon-alpha therapy for hepatitis C – a pilot study. Dig Dis Sci.
  108. Prevention of interferonalpha associated depression in psychiatric risk patients with chronic hepatitis C.
  109. (2003). Projecting future complications of chronic hepatitis C in the United States. Liver Transpl.
  110. Promoter polymorphisms of the interferon-alpha receptor gene and development of Interferon-induced depressive symptoms in patients with chronic hepatitis C: preliminary findings.
  111. Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study.
  112. Psychiatric comorbidity among hepatitis C-positive patients.
  113. Psychiatric complications of long-term interferon alfa therapy.
  114. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions.
  115. Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C.
  116. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy.
  117. (2005). Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response. Mol Psychiatry.
  118. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms.
  119. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients.
  120. (1996). Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group. Hepatology.
  121. (2009). Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry.
  122. Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis
  123. Side effects of high-dose interferon therapy for chronic hepatitis C.
  124. Subthreshold mania as predictor of depression during interferon treatment in HCV+ patients without current or lifetime psychiatric disorders.
  125. Suicide associated with alfa-interferon therapy for chronic viral hepatitis.
  126. (2010). Surveillance and epidemiology of hepatitis B and C
  127. (2010). Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther.
  128. The changing epidemiology of hepatitis C virus infection in Europe.
  129. The gem interacting protein (GMIP) gene is associated with major depressive disorder.
  130. (2006). The genetics of depression: a review. Biol Psychiatry.
  131. (2010). The genetics of major depression: moving beyond the monoamine hypothesis. Psychiatr Clin North Am.
  132. The HPA and immune axes in stress: the involvement of the serotonergic system.
  133. (1992). The interaction of some centrally active drugs with the blood-brain barrier and circumventricular organs. Prog Brain Res.
  134. (2000). The malaise theory of depression: major depressive disorder is sickness behavior and antidepressants are analgesic. Med Hypotheses.
  135. The pathogenesis of clinical depression: stressor- and cytokine-induced alterations of neuroplasticity.
  136. The phenomenology and treatment of interferoninduced depression.
  137. (2005). The power of sample size and homogenous sampling: association between the 5-HTTLPR serotonin transporter polymorphism and major depressive disorder. Biol Psychiatry.
  138. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, doubleblind, placebo-controlled study.
  139. Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders.
  140. (2001). Treatment with interferonalpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation. Mol Psychiatry.